Rocket Pharma delists 2026 warrant from Nasdaq

Rocket Pharmaceuticals, Inc. (RCKT) is having a class of its securities, described as a warrant expiring on September 2, 2026, removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. (RCKT) is having a class of its securities, described as a warrant expiring on September 2, 2026, removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.

Nasdaq states that it has complied with its own rules to strike this class from listing, and that Rocket Pharmaceuticals has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class from listing and registration.

Key Figures

Warrant expiration date: September 2, 2026

1 metrics

Warrant expiration date September 2, 2026 Expiration date of the Rocket Pharmaceuticals warrant class being removed from listing and/or registration

Key Terms

Form 25, Section 12(b) of the Securities Exchange Act of 1934, voluntary withdrawal, 17 CFR 240.12d2-2

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) of the Securities Exchange Act of 1934 regulatory

"registration under Section 12(b) of the Securities Exchange Act of 1934"

voluntary withdrawal regulatory

"governing the voluntary withdrawal of the class of securities"

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

FAQ

What security of RCKT is affected by this Form 25 filing?

The filing covers a class of Rocket Pharmaceuticals securities described as a warrant expiring on September 2, 2026, which is being removed from listing and/or registration on Nasdaq under Section 12(b).

Is Rocket Pharmaceuticals (RCKT) voluntarily withdrawing this warrant from Nasdaq?

Yes. The filing states that Rocket Pharmaceuticals has complied with exchange rules and 17 CFR 240.12d2-2(c), which governs the voluntary withdrawal of a class of securities from listing and registration.

Which exchange is delisting the Rocket Pharmaceuticals (RCKT) warrant?

The class of Rocket Pharmaceuticals warrant expiring September 2, 2026 is being removed from listing and/or registration on the Nasdaq Stock Market LLC, as certified by Nasdaq in the notification.

Under what law is the RCKT warrant being removed from listing?

The removal of the Rocket Pharmaceuticals warrant from listing and/or registration is made under Section 12(b) of the Securities Exchange Act of 1934 and the related SEC rule 17 CFR 240.12d2-2.

Who signed the Form 25 for the Rocket Pharmaceuticals (RCKT) warrant?

The notification was signed on behalf of Nasdaq Stock Market LLC by Jennifer Fainer, identified as a CDO Analyst, certifying Nasdaq’s reasonable grounds for filing the Form 25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:23 PM Accepted by SEC EDGAR 09/02/2026 - 04:23 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-36829

Issuer:	ROCKET PHARMACEUTICALS, INC.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	350 Fifth Avenue
	Suite 7530
	New York	NEW YORK	10118
Telephone number:					646-440-9100

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Warrant expires 9/2/2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-09-02	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.